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Purpose: This study investigates the effects of temporary tissue expanders (TTEs) on the dose distributions in 
breast cancer radiotherapy treatments under a variety of conditions.  
Methods: Using EBT2 radiochromic film, both electron and photon beam dose distribution measurements were 
made for different phantoms, and beam geometries. This was done to establish a more comprehensive 
understanding of the implant’s perturbation effects under a wider variety of conditions.  
Results: The magnetic disk present in a tissue expander causes a dose reduction of approximately 20% in a 
photon tangent treatment and 56% in electron boost fields immediately downstream of the implant. The effects 
of the silicon elastomer are also much more apparent in an electron beam than a photon beam  
Conclusions: Evidently, each component of the TTE attenuates the radiation beam to different degrees. This 
study has demonstrated that the accuracy of photon and electron treatments of post-mastectomy patients is 
influenced by the presence of a tissue expander for various beam orientations. The impact of TTEs on dose 
distributions establishes the importance of an accurately modelled high-density implant in the treatment 
planning system for post-mastectomy patients. 
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I. INTRODUCTION 
This study examines the dosimetric effects of temporary tissue expanders (TTEs) on 
radiotherapy treatments. TTEs are used in post-mastectomy breast reconstructions for 
selected breast cancer patients. Since radiotherapy treatment is usually started 4 to 8 weeks 
after the mastectomy surgery, some patients undergo radiotherapy with the TTE present. 
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These TTEs are made of a membrane composed of silicone elastomer, a chemically inert and 
mechanically robust material. The silicone membrane needs to be periodically filled with a 
saline solution until the desired expansion is reached. A magnetic disk allows the position of 
the implant’s valve to be determined inside the patient’s body. This high-density disk has the 
potential to seriously compromise the accuracy of radiotherapy treatment planning dose 
calculations, and hence delivery [1].  
 
Several studies have been reported examining the effects of tissue expanders on radiotherapy 
dosimetry. Moni et. al. [2] completed measurements around the magnetic valve of a McGhan 
(Inamed/Allergan) tissue expander using film and thermoluminescent dosimeters (TLD) for a 
6 MV photon beam. These measurements were designed to look for increased dose around 
the port, due to scatter from the high density metal, and found that there was no increased 
dose in the region of the metallic port. However, the results showed a decrease in the dose 
measured directly under the metallic port of around 25% in a region of 1.7 to 3.7 cm 
downstream. Damast et. al. [3] also investigated the effect of a McGhan Style 133 
(Inamed/Allergan) tissue expander in a radiotherapy treatment using films and TLDs. Similar 
underdosing was identified but the authors concluded that this was not clinically significant 
due to the small volume of tissue underdosed. Chatzigiannis et. al. [4] performed Monte 
Carlo simulations using CT images of a patient implanted with a McGhan Style 133 
(Inamed/Allergan) tissue expander. The magnet of the valve was simulated as being 
composed by Neodymium-iron-boron. Attenuation of 6–13% was found through all the area 
in the shadow of the magnetic valve and a dose enhancement around 10% was found near the 
metallic structure. Thompson and Morgan’s [5] diode measurements described an 11% dose 
enhancement in a region of 5 mm around the valve and an underdosing of 10% to the 
radiation target when tangential photon beams were used.  
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Notably, all of these studies [2–5] examined the effects of only one type of tissue expander 
(McGhan Inamed/Allergan) on photon-beam dose distributions. Their findings showed 
conflicting reports on backscatter measurements and differing magnitudes of dose reduction. 
Finally, since breast-cancer patients with tissue expanders continue to be treated with both 
photon and electron-beam radiotherapy, there is an obvious need for a thorough examination 
of the effects of these implants on the doses delivered by both tangential photon fields and 
electron boost fields.  
 
A recently published study by Srivastava et. al. [6] compared ion chamber measurements 
with treatment planning system (TPS) calculations and concluded that high-Z materials 
should be avoided due to their poor modeling in TPS algorithms. This failure to accurately 
calculate dose distributions could be attributed to incorrect CT density assignments for high-
Z materials [7]. Irrespective of TPS inaccuracies, the avoidance of a high-density port is not a 
practical option in post-mastectomy radiotherapy and may result in sub-optimal treatments 
being delivered to the patient. Therefore, in the present study we experimentally examine the 
effects of a Mentor TTE (Mentor, Magna-Site disk, Santa Clara, CA, USA) on electron and 
photon beam dose distributions. Exploring different phantoms and beam geometries will 
provide a more comprehensive understanding of the effects of tissue expanders in post-
mastectomy radiotherapy. 
 
II. METHODS 
In this study, dose distribution measurements around a Mentor TTE were performed using 
EBT2 radiochromic film. The implant was partially filled with 250 cm
3
 of a 0.9% saline 
solution, and then placed atop a planar phantom composed of an arrangement of water and 
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lung equivalent materials, illustrated in Figure 1. Additionally, a 1.5 cm layer of bolus was 
placed over the top of the implant such that the phantom set-up models the subcutaneous 
implantation of the expander in a patient. Pieces of film were then positioned 0 cm and 2 cm 
downstream of the implant as well as one piece of film immediately upstream to measure any 
backscatter caused by the high-Z material. The TTE was irradiated isocentrically (98.5cm 
SSD) using a 15x15 cm
2
 field of 6 MV photons, as well as 12 MeV electrons, at incidences 
perpendicular to the heterogeneity. 
 
Figure 1 Illustration of the planar phantom arrangement, TTE placement, and film locations (thick black lines) 
during photon and electron beam irradiations (bolus not shown). 
Measurements were also made using a CIRS IMRT thorax phantom, this time with the TTE 
filled with 400 cm
3
 of the saline solution. Once again, a 15x15 cm
2
, 6 MV photon field was 
delivered at an incidence perpendicular to the heterogeneity (gantry angle of 340
o
). Once 
more, film was placed above and below the implant. An additional piece was placed running 
parallel to the incident beam between slices of the thorax phantom. Fig. 2 demonstrates the 
alignment of our experimental conditions to a clinical case with a CT slice of the thorax /TTE 
phantom and overlying bolus compared to an image slice of a patient with the subcutaneous 
implantation of a tissue expander. 
Beam Direction 
1 cm solid water 
1 cm solid water 
6 cm foam (lung equivalent) 
2 cm solid water 
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Figure 2 (a) CT slice of the thorax phantom indicating beam angles and TTE placement. (b) Image slice of a 
patient with implanted tissue expander. 
 
Finally, a beam arrangement was adopted from a clinical plan where photon tangents were 
modulated using a forward-planned IMRT (field-in-field) technique [8,9]. This involved 
delivering segmented, tangent photon fields (dynamic wedged fields) at angles of 70
o 
and 
250
o
 with film placed immediately upstream and downstream of the implant. The technique 
has been shown to provide more homogeneous dose distributions in the planning target 
volume (PTV) and reduced doses in the organs at risk (OAR) [10].  
 
The film was scanned and evaluated as per the protocol outlined in Kairn et. al. [11] and 
Aland et. al. [12] which minimised the effects of film heterogeneity and scanner output 
variations. Finally, the dose reduction values presented in this work were calculated as the 
percentage difference between the average doses outside the shadow of the magnet, relative 
to the doses in the region directly under the magnet. Measurement uncertainties were taken as 
the standard deviation of doses in each region. 
 
340
o
 
70
o
 
250
o
 
(a) (b) 
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III. RESULTS AND DISCUSSION 
Fig. 3 shows the dose profile of the implant at two different depths, downstream of the breast 
implant in the planar phantom for a 6 MV photon beam at 0
o
 gantry. At 0 cm, in the region 
directly below the magnetic valve, the dose is reduced by as much as 15 ± 3 %. This figure 
also reports a 12 ± 2 % dose reduction at 2 cm below the bottom edge of the implant. No 
backscatter dose enhancements were reported in the radiochromic film and were therefore not 
included in Fig. 1.  
 
Figure 3 Dose profiles of a 6 MV photon beam at different depths downstream of the implant. Inset indicates 
beam direction, film locations (thick black lines), and profile positions. 
 
The qualitative data, displayed in Fig. 4 (a), clearly illustrates the perturbation effects the 
high-density magnetic port, as well as the silicone elastomer in the 12 MeV electron beam at 
different depths. Increased bremsstrahlung around the edges of the implant is also visible. 
 
6 MV Photon 
Beam Direction 
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Figure 4 (a) Images of scanned EBT2 film showing attenuation of the 12 MeV electron beam through the 
temporary tissue expander at 0 cm (left) and 2 cm (right) downstream. (b) Corresponding central-axis profile 
plots at different depths downstream of the tissue expander. Inset indicates beam direction and film locations 
(thick black lines). 
 
12 MeV Electron 
Beam Direction 
(b) 
(a) 
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Fig. 4 (b) shows the dose profile of the TTE in a 12 MeV electron boost field at two distances 
downstream of the implant in a planar phantom. At 0 cm a substantial dose reduction of 
approximately 56 ± 6 % is reported compared to the dose recorded outside the magnet’s field 
shadow. It should be noted that the at the location of the profile taken outside of the magnet’s 
shadow there is a slight difference of overlaying tissue thickness compared to that taken in 
the magnet’s shadow due to the curvature of the implant surface, however the difference to 
the dose profile is negligible in comparison to the effect of the metallic port.  Given that boost 
fields are typically delivered as per this experimental setup, electron treatments of post-
mastectomy patients with TTEs would be compromised by the presence of this high-Z 
material. The effects of the silicon elastomer are also much more apparent in the electron 
beam than the photon beam.  
 
Photon beam measurements in the CIRS IMRT thorax phantom illustrate the perturbation 
effects of each component of the implant and are shown in Fig. 5. Moving averages have 
been applied to smooth the data which helps illustrate the magnitude of each component’s 
attenuation. 
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Figure 5 6 MV photon depth dose profiles in the CIRS thorax phantom downstream of different components in 
the implant with filled volume. Insets indicate approximate profile locations and beam direction. 
 
From Fig. 5, it was determined that profiles downstream of the silicone elastomer/saline 
interface averaged doses around 8% lower when compared to profiles taken outside the 
implant’s shadow. Differences for profiles taken under the titanium case, titanium ring and 
neodymium magnet were approximately 12%, 15% and 19% respectively. These results 
agree with what is expected when considering the scaled depth of each implant component 
and its density. It should be noted that there are slight differences in depth caused by the 
curved shape of the implant; however, this would have no effect on the order of which 
components attenuate the most. This highlights the importance for an accurately modelled 
high-density implant in the treatment planning system. 
 
340
o
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Photon tangent fields were also delivered to the thorax phantom and the results in Fig. 6 
illustrate a combined dose reduction of 20% caused by the high-density magnet in both 
treatment directions, calculated once again using the percentage difference between the 
average dose values outside the shadow of the magnet, relative to the dose value in the region 
directly downstream of the magnetic port.  Given that post-mastectomy treatments are 
typically delivered as per this experimental setup, the impact of the TTE on photon dose 
distributions would be significant if it’s not accurately accounted for in planning. The insets 
indicate in Fig. 6 indicate the approximate profile locations as well as pictographically 
demonstrating the perturbation caused by the TTE’s internal magnet and silicone elastomer 
shell. 
 
Figure 6 Dose profiles of a 6 MV photon treatment for two beam tangents at gantry angles of 70o and 250o. The 
data has been smoothed with the application of a moving average filter. Insets indicate beam directions and 
approximate profile locations/directions on downstream film pieces. 
70
o
 
250
o
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IV. CONCLUSIONS 
This work indicates that the magnetic disk present in a tissue expander causes an average 
dose reduction of approximately 20% in photon tangent fields and 56% in electron boost 
fields immediately downstream of the implant. The silicone elastomer shell of the Mentor 
implant has also been shown to reduce the dose to a section of the target volume by as much 
as 8% in a 6 MV photon field, which in turn reduces the probability of tumour control. 
Evidently, each component of the TTE attenuates the radiation beam to different degrees. 
This highlights the importance for an accurately modelled high-density implant in the 
treatment planning system for post-mastectomy patients.  
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